Johnson & Johnson (NYSE:JNJ) Shares Sold by Morris Financial Concepts Inc.

Morris Financial Concepts Inc. trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 3.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 3,147 shares of the company’s stock after selling 114 shares during the period. Morris Financial Concepts Inc.’s holdings in Johnson & Johnson were worth $455,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in JNJ. Vinva Investment Management Ltd boosted its stake in shares of Johnson & Johnson by 6.8% during the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock worth $17,988,000 after purchasing an additional 7,110 shares during the last quarter. Financial Counselors Inc. boosted its stake in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock worth $29,996,000 after purchasing an additional 9,309 shares during the last quarter. Oregon Pacific Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $949,000. Meridian Investment Counsel Inc. boosted its stake in shares of Johnson & Johnson by 19.6% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock worth $3,667,000 after purchasing an additional 3,710 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock worth $2,858,543,000 after purchasing an additional 102,502 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.7 %

JNJ opened at $156.20 on Monday. The firm has a market capitalization of $376.08 billion, a P/E ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. The firm’s 50 day moving average is $147.87 and its 200-day moving average is $155.96. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the firm posted $2.29 earnings per share. The business’s quarterly revenue was up 5.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Leerink Partners cut their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Finally, Bank of America cut their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.